{
  "id": 18146941,
  "title": "Sanofi ends development of Nurix's STAT6 degrader",
  "url": "https://urgent.news/2026/11/04/sanofi-ends-development-of-nurixs-stat6-degrader",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-04T16:05:02.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/sanofi-ends-development-of-nurixs-stat6-degrader/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Sanofi is dropping an experimental drug targeting a pathway that many analysts see as a potential pillar of the next generation of immunology medicine. The company will no longer pursue the program known as SAR448272 ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}